Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the dallas heart study

Clinical Chemistry

Volumn 59, Issue 3, 2013, Pages 536-546

  Chen, Lu Q ^a,b   De Lemos, James A ^a,b   Das, Sandeep R ^b,c   Ayers, Colby R ^a,c   Rohatgi, Anand ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Donald W Reynolds Cardiovascular Clinical Research Center   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CELL ADHESION MOLECULE; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR; LUNG SURFACTANT; LYMPHOTOXIN BETA RECEPTOR; PULMONARY SURFACTANT PROTEIN B; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE ST2 PROTEIN; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INFLAMMATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION RESEARCH;

ADULT; AFRICAN AMERICANS; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; RISK FACTORS;

EID: 84874610413     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.191106     Document Type: Article

References (40)

1. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106: 2961-6.
2. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999;264:397-406.
3. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117: 1538-49.
4. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-46.
5. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107: 259-67.
6. Shah KB, Kop WJ, Christenson RH, Diercks DB, Henderson S, Hanson K, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 2011; 57:874-82.
7. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4:180-7.
8. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6.
9. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: Comparison with global registry of acute coronary events risk scoring and NT-proBNP. Am Heart J 2011;161: 1163-70.
10. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, James SK. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010;159:788-94.
11. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004;93: 1473-80.
12. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121:e46-e215.
13. Jain T, Peshock R, McGuire DK, Willett D, Yu Z, Vega GL, et al. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol 2004; 44:1011-7.
14. Rohatgi A, Ayers CR, Khera A, McGuire DK, Das SR, Matulevicius S, et al. The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: observations from the Dallas Heart Study. Atherosclerosis 2009;203: 569-75.
15. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005;46:124-9.
16. Rohatgi A, Patel P, Das SR, Ayers CR, Khera A, Martinez-Rumayor A, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multi-ethnic population: observations from the Dallas Heart Study. Clin Chem 2011.
17. Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart study. Circ Heart Fail 2009;2:98-104.
18. Matulevicius S, Rohatgi A, Khera A, Das SR, Owens A, Ayers CR, et al. The association between plasma caspase-3, atherosclerosis, and vascular function in the Dallas Heart Study. Apoptosis 2008;13:1281-9.
19. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005;46:464-9.
20. Nguyen AB, Rohatgi A, Garcia CK, Ayers CR, Das SR, Lakoski SG, et al. Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2011; 31:2136-43.
21. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007;99: 513-8.
22. Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of N-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 2005;96:1284-9.
23. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503-12.
24. Owens AW, Matulevicius S, Rohatgi A, Ayers CR, Das SR, Khera A, et al. Circulating lymphotoxin beta receptor and atherosclerosis: observations from the Dallas Heart Study. Atherosclerosis 2010;212:601-6.
25. Rohatgi A, Owens AW, Khera A, Ayers CR, Banks K, Das SR, et al. Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule. Arterioscler Thromb Vasc Biol 2009;29: 1684-90.
26. Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009;32:1218-20.
27. Turer AT, Khera A, Ayers CR, Turer CB, Grundy SM, Vega GL, Scherer PE. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011;54:2515-24.
28. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007;50:2117-24.
29. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A, et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2007;27:2043-9.
30. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011;30:22-38.
31. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-72; discussion 207-12.
32. D'Agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR, eds. Handbook of statistics, Vol. 23. New York: Elsevier 2003;1-25.
33. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
34. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-40.
35. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008;52:2166-74.
36. Havranek EP, Froshaug DB, Emserman CD, Hanratty R, Krantz MJ, Masoudi FA, et al. Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity. Am J Med 2008;121: 870-5.
37. Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011;31:2080-9.
38. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007;179:2551-5.
39. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the iL-1 receptorrelated protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90.
40. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010;49:520-7.